Crossing the Pacific: Genomics Reveals the Presence of Japanese Sardine (Sardinops melanosticta) in the California Current Large Marine Ecosystem.

Autor: Longo GC; National Marine Fisheries Service, Southwest Fisheries Science Center, Ocean Associates, Inc., Under Contract to the National Oceanic and Atmospheric Administration, La Jolla, California, USA., Minich JJ; The Plant Molecular and Cellular Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA., Allsing N; The Plant Molecular and Cellular Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA., James K; National Marine Fisheries Service, Southwest Fisheries Science Center, National Oceanographic and Atmospheric Administration, La Jolla, California, USA., Adams-Herrmann ES; National Marine Fisheries Service, Southwest Fisheries Science Center, Ocean Associates, Inc., Under Contract to the National Oceanic and Atmospheric Administration, La Jolla, California, USA.; University of San Diego, San Diego, California, USA.; University of Central Florida, Department of Biology, Orlando, FL, USA., Larson W; National Oceanographic and Atmospheric Administration, National Marine Fisheries Service, Alaska Fisheries Science Center, Auke Bay Laboratories, Juneau, Alaska, USA., Hartwick N; The Plant Molecular and Cellular Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA., Duong T; The Plant Molecular and Cellular Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA., Muhling B; National Marine Fisheries Service, Southwest Fisheries Science Center, National Oceanographic and Atmospheric Administration, La Jolla, California, USA.; Institute of Marine Sciences Fisheries Collaborative Program, University of California, Santa Cruz, Santa Cruz, California, USA., Michael TP; The Plant Molecular and Cellular Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA., Craig MT; National Marine Fisheries Service, Southwest Fisheries Science Center, National Oceanographic and Atmospheric Administration, La Jolla, California, USA.

Publikováno v: Molecular ecology [Mol Ecol] 2024 Nov; Vol. 33 (22), pp. e17561. Date of Electronic Publication: 2024 Oct 23.

Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder.

Autor: Lee DC; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: dlee214@jhmi.edu., Schlienz NJ; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA., Herrmann ES; Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, 20892, USA., Martin EL; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA., Leoutsakos J; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA., Budney AJ; Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA., Smith MT; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA., Tompkins DA; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco School of Medicine, San Francisco, CA, USA., Hampson AJ; Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, 20892, USA., Vandrey R; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Publikováno v: Journal of substance use and addiction treatment [J Subst Use Addict Treat] 2024 Jan; Vol. 156, pp. 209180. Date of Electronic Publication: 2023 Oct 05.

National Institute on Drug Abuse (NIDA) research priorities to support the development of incentive-based treatments for substance use disorders.

Autor: Aklin WM; National Institute on Drug Abuse, Division of Therapeutics and Medical Consequences, USA. Electronic address: aklinwm@mail.nih.gov., Herrmann ES; National Institute on Drug Abuse, Division of Therapeutics and Medical Consequences, USA.

Publikováno v: Preventive medicine [Prev Med] 2023 Nov; Vol. 176, pp. 107650. Date of Electronic Publication: 2023 Jul 29.

Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers.

Autor: Haney M; New York State Psychiatric Institute, New York, New York, USA.; Columbia University Irving Medical Center, New York, New York, USA., Bedi G; Centre for Youth Mental Health, The University of Melbourne and Substance Use Research Group, Orygen, Melbourne, Australia., Cooper ZD; Los Angeles Cannabis Research Initiative, Jane & Terry Semel Institute for Neuroscience & Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA., Herrmann ES; Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, Bethesda, Maryland, USA., Reed SC; New York State Psychiatric Institute, New York, New York, USA.; Columbia University Irving Medical Center, New York, New York, USA., Foltin RW; New York State Psychiatric Institute, New York, New York, USA.; Columbia University Irving Medical Center, New York, New York, USA., Kingsley PJ; A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry, and Pharmacology, Vanderbilt University, Nashville, Tennessee, USA., Marnett LJ; A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry, and Pharmacology, Vanderbilt University, Nashville, Tennessee, USA., Patel S; Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Publikováno v: Addiction biology [Addict Biol] 2022 Jul; Vol. 27 (4), pp. e13183.

A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans.

Autor: Arout CA; Division on Substance Use Disorders, New York Psychiatric Institute and Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA., Haney M; Division on Substance Use Disorders, New York Psychiatric Institute and Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA., Herrmann ES; Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, USA., Bedi G; Centre for Youth Mental Health, The University of Melbourne and Substance Use Research Group, Melbourne, Australia., Cooper ZD; University of California, Los Angeles Cannabis Research Initiative, Jane & Terry Semel Institute for Neuroscience & Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, USA.; Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Jan; Vol. 88 (1), pp. 347-355. Date of Electronic Publication: 2021 Jul 23.